业界动态国内医卫资讯
STAT+：礼来的三靶点G药物在头对头研究中击败奥泽匹克
STAT News · 2026-10-28 21:42
摘要
想随时了解驱动当今生物科技的科学与政策吗？注册即可在邮箱中收到我们的生物科技新闻通讯。早上好。今天有很多新闻要讲。礼来的三靶点G药物在头对头研究中击败奥泽匹克——礼来今早表示，在一项大型糖尿病研究中，其研究性药物瑞他鲁肽在降低血糖和减重方面比诺和诺德的奥泽匹克更有效。继续阅读STAT+以获取完整报道……
English
STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got lots of news today to get into. Lilly’s triple-G drug beats Ozempic in head-to-head study Eli Lilly said this morning that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study. Continue to STAT+ to read the full story…